Module
-
Robotics
Synaptive Medical Receives FDA 510(k) Clearance for Near-Infrared Fluorescence Visualization, Expanding Application of Existing Robotic Exoscope
Near-Infrared fluorescence now available on Modus X robotic exoscope, complementing system’s existing advanced fluorescence capabilities New Infrared fluorescence enables the…
Read More » -
Regulatory
VisionGauge® Bone Screw Inspection & Measurement Module Provides Medical Manufacturers with Crucial Benefits
The VisionGauge® Digital Optical Comparator offers new technology for drastic inspection advancements and overall cost reduction for medical bone screw…
Read More » -
Hospitals
Activ Surgical Secures CE Mark Approval for ActivSight™ Intelligent Light
ActivSight™ Intelligent Light, an easy-to-adapt module that seamlessly attaches to today’s laparoscopic systems providing real-time, on-demand surgical insights integrated into…
Read More » -
Spine
SeaSpine Announces Full Commercial Launch of the 7D FLASH™ Navigation System Percutaneous Spine Module for Minimally Invasive Surgery
CARLSBAD, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on…
Read More » -
Spine
AxioMed LLC Submits Final Module III to the FDA Becoming the First and Only Lumbar Viscoelastic Total Disc Replacement Company to Complete a USA IDE Clinical Trial
On August 8, 2022, AxioMed LLC submitted to the FDA all the required documents for Module III. This is the…
Read More » -
Spine
FDA Accepts & Closes Empirical Spine’s LimiFlex™ PMA Module II As A Motion-Preserving Alternative To Lumbar Fusion
SAN CARLOS, Calif., July 13, 2022 /PRNewswire/ — Empirical Spine, Inc., a medical device company creating a new class of spinal implant…
Read More » -
Regulatory
AxioMed Announces Progress with Completing Module I-III Lumbar FDA Submission of The First Lumbar Viscoelastic Disc Replacement to Complete a US IDE Clinical Study
AxioMed presses forward on its FDA submission of documents needed to complete the last Module III of its FDA application…
Read More »